Neratinib extends 5-yr invasive DFS in HER-2–high quality breast melanoma - Healio

[unable to retrieve full-text content]OncLiveNeratinib extends 5-12 months i nvasive DFS in HER-2–nice breast melanomaHealioNeratinib extended 5-12 months invasive DFS compared with placebo amongst girls along with her-2–wonderful early-stage breast melanoma, in line with intervening time effects of the ExteNET trial released with the aid of the drug's brand.Neratinib benefit in Breast cancer Sustained in 5-yr ExteNET evaluationOncLiveall 5 information articles »